Hospital
Prime Healthcare LA Palma, LLC
Prime Healthcare LA Palma, LLC was paid $3.02M by Medicaid between Jan 2018 and Dec 2024, across 106 billing codes. Its largest line is 0450, Emergency room services — 20% of everything it billed.
33Billing provider infoPRIME HEALTHCARE LA PALMA, LLC
LA PALMA, CA 90623
LA PALMA, CA 90623
33aNPI1417965559assigned 08/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.02M
24GClaims247,089
24DCodes billed106
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#243 of 410
Median peer was paid$6.90M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,533 | $435K | |
| 2019 | 37,688 | $464K | |
| 2020 | 30,076 | $345K | |
| 2021 | 31,965 | $345K | |
| 2022 | 43,260 | $485K | |
| 2023 | 41,640 | $600K | |
| 2024incomplete | 22,927 | $344K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 20% | 28,429 | 24,987 | $606K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.7% | 6,140 | 5,125 | $232K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.5% | 2,526 | 2,344 | $166K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 921 | 785 | $137K |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.8% | 3,080 | 2,015 | $114K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.6% | 4,418 | 3,955 | $108K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.1% | 3,886 | 3,203 | $93K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 1,170 | 1,043 | $88K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 6,433 | 5,414 | $88K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.5% | 1,566 | 1,343 | $74K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 717 | 681 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 4,683 | 3,540 | $73K |
94 more codes
| J3490 | Unclassified drugs | 2.2% | 13,934 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 1,721 | $66K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 4,158 | $65K |
| 80053 | Comprehensive metabolic panel | 2.1% | 10,167 | $62K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 12,968 | $58K |
| 0270 | 1.6% | 24,669 | $49K | |
| Z7502 | 1.6% | 1,261 | $47K | |
| 99284 | Emergency room visit (serious) | 1.5% | 999 | $46K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,001 | $45K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 5,277 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,206 | $44K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,089 | $42K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 2,473 | $41K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 7,120 | $38K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.2% | 8,436 | $36K |
| 99283 | Emergency room visit (moderate) | 1.2% | 1,586 | $36K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.1% | 6,027 | $34K |
| 99199 | Unlisted special service, procedure or report | 1.1% | 746 | $33K |
| 83690 | 1.0% | 7,840 | $31K | |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 4,647 | $27K |
| 84484 | <1% | 4,078 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,473 | $18K |
| 81025 | <1% | 6,017 | $18K | |
| 81001 | <1% | 8,602 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,436 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,793 | $14K |
| 0250 | <1% | 5,284 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,940 | $12K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,718 | $11K |
| Z7610 | <1% | 907 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,211 | $11K |
| 0271 | <1% | 4,662 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,346 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 520 | $7K |
| 0272 | <1% | 4,397 | $6K | |
| 87040 | <1% | 892 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 40 | $4K |
| 83605 | <1% | 698 | $4K | |
| 73562 | <1% | 227 | $4K | |
| 73610 | <1% | 200 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 545 | $3K |
| 83880 | <1% | 202 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 668 | $3K |
| 90715 | <1% | 112 | $3K | |
| 87186 | <1% | 632 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 461 | $2K |
| 85610 | <1% | 912 | $2K | |
| 73030 | <1% | 119 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 46 | $2K |
| 73630 | <1% | 110 | $2K | |
| 82962 | <1% | 1,376 | $2K | |
| 87070 | <1% | 636 | $2K | |
| 99406 | <1% | 262 | $2K | |
| 94760 | <1% | 316 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,063 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 216 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 302 | $1K |
| 87420 | <1% | 369 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 51 | $1K |
| 85379 | <1% | 177 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 32 | $1K |
| 85730 | <1% | 311 | $1K | |
| 85027 | <1% | 719 | $621.42 | |
| 0636 | <1% | 245 | $558.77 | |
| 0011A | <1% | 12 | $480.00 | |
| Z9725 | <1% | 13 | $390.00 | |
| 87088 | <1% | 92 | $375.57 | |
| 99070 | <1% | 120 | $333.98 | |
| 84702 | <1% | 41 | $292.10 | |
| 73130 | <1% | 16 | $278.53 | |
| 0301 | <1% | 174 | $255.80 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 60 | $214.89 |
| 73110 | <1% | 13 | $209.95 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16 | $173.60 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16 | $173.50 |
| 74018 | <1% | 14 | $150.71 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 27 | $135.89 |
| 80076 | <1% | 27 | $122.88 | |
| 29125 | <1% | 48 | $118.25 | |
| 87184 | <1% | 44 | $117.12 | |
| 86901 | <1% | 41 | $116.57 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 32 | $116.04 |
| A4649 | Surgical supply; miscellaneous | <1% | 279 | $108.21 |
| 96376 | <1% | 70 | $105.12 | |
| 86900 | <1% | 41 | $93.11 | |
| 87205 | <1% | 47 | $79.86 | |
| 82947 | <1% | 30 | $57.28 | |
| 82550 | <1% | 14 | $44.43 | |
| A4657 | Syringe, with or without needle, each | <1% | 13 | $26.56 |
| A4215 | Needle, sterile, any size, each | <1% | 24 | $3.15 |
| 0305 | 0% | 77 | $0.00 | |
| 0324 | 0% | 18 | $0.00 | |
| 0306 | 0% | 28 | $0.00 | |
| 0320 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDY, PREM (CHAIRMAN/PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Prime Healthcare Services Mesquite LLC | Mesquite, TX | $6.58M |
| Prime Healthcare Services - Sherman Oaks, LLC | Sherman Oaks, CA | $5.68M |
| Paradise Valley Medical Group, INC. | National City, CA | $2.50M |
| Ohio Valley Home Care, LLC | East Liverpool, OH | $196K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.